547 related articles for article (PubMed ID: 19175607)
1. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
2. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
3. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
Bertotti A; Comoglio PM; Trusolino L
Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
[TBL] [Abstract][Full Text] [Related]
4. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
5. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
6. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
7. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
8. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
9. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
10. Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3.
Cramer A; Kleiner S; Westermann M; Meissner A; Lange A; Friedrich K
J Cell Biochem; 2005 Jul; 95(4):805-16. PubMed ID: 15838885
[TBL] [Abstract][Full Text] [Related]
11. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
13. A novel germ line juxtamembrane Met mutation in human gastric cancer.
Lee JH; Han SU; Cho H; Jennings B; Gerrard B; Dean M; Schmidt L; Zbar B; Vande Woude GF
Oncogene; 2000 Oct; 19(43):4947-53. PubMed ID: 11042681
[TBL] [Abstract][Full Text] [Related]
14. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS
Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
16. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
17. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu X; Powlas J; Shi Y; Oleksijew AX; Shoemaker AR; De Jong R; Oltersdorf T; Giranda VL; Luo Y
Anticancer Res; 2004; 24(5A):2697-704. PubMed ID: 15517874
[TBL] [Abstract][Full Text] [Related]
19. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
[TBL] [Abstract][Full Text] [Related]
20. GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation.
Cazet A; Lefebvre J; Adriaenssens E; Julien S; Bobowski M; Grigoriadis A; Tutt A; Tulasne D; Le Bourhis X; Delannoy P
Mol Cancer Res; 2010 Nov; 8(11):1526-35. PubMed ID: 20889649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
